References
- Mangiacavalli S, Albani G, Caravita T, . Similar neurotoxicity of an alternating compared to a continuous low-dose schedule of thalidomide for relapsed/refractory multiple myeloma. Leuk Lymphoma 2011;52: press.
- Lokhorst HM, van der Holt B, Zweegman S, . A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010;115:1113–1120.
- Wijermans P, Schaafsma M, Termorshuizen F, . Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol 2010;28:3160–3166.
- Cavo M, Tacchetti P, Patriarca F, . Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010;376:2075–2085.
- Palumbo A, Bringhen S, Rossi D, . Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010;28:5101–5109.
- Yasuda H, Ando J, Sato E, . Successful treatment of extramedullary tumors with low-dose thalidomide in patients with multiple myeloma. Intern Med 2010;49:2617–2620.
- Bringhen S, Larocca A, Rossi D, . Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010;116:4745–4753.
- Reeder CB, Reece DE, Kukreti V, . Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood 2010;115:3416–3417.
- Moreau P, Pylypenko H, Grosicki S, . Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011;12:431–440.
- Johnson DC, Corthals SL, Walker BA, . Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol 2011;29:797–804.
- Broyl A, Corthals SL, Jongen JL, . Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol 2010;11:1057–1065.
- Favis R, Sun Y, van de Velde H, . Genetic variation associated with bortezomib-induced peripheral neuropathy. Pharmacogenet Genomics 2011;21:121–129.